Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, aripiprazole and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Bifeprunox may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Bifeprunox. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Bifeprunox. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Bifeprunox. |
| Hydrocodone | Bifeprunox may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Bifeprunox. |
| Magnesium sulfate | The therapeutic efficacy of Bifeprunox can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Bifeprunox may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Bifeprunox may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Bifeprunox. |
| Mirtazapine | Bifeprunox may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Bifeprunox. |
| Orphenadrine | Bifeprunox may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Bifeprunox may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Bifeprunox. |
| Pramipexole | Bifeprunox may increase the sedative activities of Pramipexole. |
| Ropinirole | Bifeprunox may increase the sedative activities of Ropinirole. |
| Rotigotine | Bifeprunox may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Bifeprunox. |
| Sodium oxybate | Bifeprunox may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Bifeprunox may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Bifeprunox. |
| Thalidomide | Bifeprunox may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Bifeprunox may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Amisulpride | Bifeprunox may increase the antipsychotic activities of Amisulpride. |
| Methylphenidate | The risk or severity of adverse effects can be increased when Bifeprunox is combined with Methylphenidate. |
| Dexmethylphenidate | The risk or severity of adverse effects can be increased when Bifeprunox is combined with Dexmethylphenidate. |
| Metoclopramide | The risk or severity of adverse effects can be increased when Metoclopramide is combined with Bifeprunox. |
| Quinagolide | The therapeutic efficacy of Quinagolide can be decreased when used in combination with Bifeprunox. |
| Sulpiride | Bifeprunox may increase the antipsychotic activities of Sulpiride. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Bifeprunox. |
| Lithium citrate | Lithium citrate may increase the neurotoxic activities of Bifeprunox. |
| Lithium hydroxide | Lithium hydroxide may increase the neurotoxic activities of Bifeprunox. |
| Mequitazine | Bifeprunox may increase the arrhythmogenic activities of Mequitazine. |
| Tetrabenazine | The risk or severity of adverse effects can be increased when Bifeprunox is combined with Tetrabenazine. |
| Deutetrabenazine | The risk or severity of adverse effects can be increased when Bifeprunox is combined with Deutetrabenazine. |
| Ethanol | Bifeprunox may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Bifeprunox may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Bifeprunox. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Bifeprunox is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Bifeprunox is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Bifeprunox is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Bifeprunox is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Bifeprunox is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Bifeprunox is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Bifeprunox is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Bifeprunox is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Bifeprunox is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Bifeprunox is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Bifeprunox is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Bifeprunox is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Bifeprunox is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Bifeprunox is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Bifeprunox. |
| Indalpine | The risk or severity of adverse effects can be increased when Bifeprunox is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Bifeprunox is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Bifeprunox is combined with Alaproclate. |
| Carbidopa | The therapeutic efficacy of Carbidopa can be decreased when used in combination with Bifeprunox. |
| Benzatropine | The therapeutic efficacy of Benzatropine can be decreased when used in combination with Bifeprunox. |
| Cabergoline | The therapeutic efficacy of Cabergoline can be decreased when used in combination with Bifeprunox. |
| Tolcapone | The therapeutic efficacy of Tolcapone can be decreased when used in combination with Bifeprunox. |
| Metixene | The therapeutic efficacy of Metixene can be decreased when used in combination with Bifeprunox. |
| Trihexyphenidyl | The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Bifeprunox. |
| Procyclidine | The therapeutic efficacy of Procyclidine can be decreased when used in combination with Bifeprunox. |
| Profenamine | The therapeutic efficacy of Profenamine can be decreased when used in combination with Bifeprunox. |
| Entacapone | The therapeutic efficacy of Entacapone can be decreased when used in combination with Bifeprunox. |
| Lisuride | The therapeutic efficacy of Lisuride can be decreased when used in combination with Bifeprunox. |
| Apomorphine | The therapeutic efficacy of Apomorphine can be decreased when used in combination with Bifeprunox. |
| Biperiden | The therapeutic efficacy of Biperiden can be decreased when used in combination with Bifeprunox. |
| Progabide | The therapeutic efficacy of Progabide can be decreased when used in combination with Bifeprunox. |
| Amantadine | The therapeutic efficacy of Amantadine can be decreased when used in combination with Bifeprunox. |
| Selegiline | The therapeutic efficacy of Selegiline can be decreased when used in combination with Bifeprunox. |
| Memantine | The therapeutic efficacy of Memantine can be decreased when used in combination with Bifeprunox. |
| Pergolide | The therapeutic efficacy of Pergolide can be decreased when used in combination with Bifeprunox. |
| Bromocriptine | The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Bifeprunox. |
| Levodopa | The therapeutic efficacy of Levodopa can be decreased when used in combination with Bifeprunox. |
| Rasagiline | The therapeutic efficacy of Rasagiline can be decreased when used in combination with Bifeprunox. |
| 3,5-Dinitrocatechol | The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Bifeprunox. |
| Etilevodopa | The therapeutic efficacy of Etilevodopa can be decreased when used in combination with Bifeprunox. |
| Safinamide | The therapeutic efficacy of Safinamide can be decreased when used in combination with Bifeprunox. |
| Ifenprodil | The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Bifeprunox. |
| Dexetimide | The therapeutic efficacy of Dexetimide can be decreased when used in combination with Bifeprunox. |
| Opicapone | The therapeutic efficacy of Opicapone can be decreased when used in combination with Bifeprunox. |
| Piribedil | The therapeutic efficacy of Piribedil can be decreased when used in combination with Bifeprunox. |
| Benserazide | The therapeutic efficacy of Benserazide can be decreased when used in combination with Bifeprunox. |
| Tropatepine | The therapeutic efficacy of Tropatepine can be decreased when used in combination with Bifeprunox. |
| Melevodopa | The therapeutic efficacy of Melevodopa can be decreased when used in combination with Bifeprunox. |
| Dihydroergocryptine | The therapeutic efficacy of Dihydroergocryptine can be decreased when used in combination with Bifeprunox. |
| Phenglutarimide | The therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Bifeprunox. |
| Mazaticol | The therapeutic efficacy of Mazaticol can be decreased when used in combination with Bifeprunox. |
| Etybenzatropine | The therapeutic efficacy of Etybenzatropine can be decreased when used in combination with Bifeprunox. |
| Budipine | The therapeutic efficacy of Budipine can be decreased when used in combination with Bifeprunox. |
| Bornaprine | The therapeutic efficacy of Bornaprine can be decreased when used in combination with Bifeprunox. |
| Etanautine | The therapeutic efficacy of Etanautine can be decreased when used in combination with Bifeprunox. |
| Dexpramipexole | The therapeutic efficacy of Dexpramipexole can be decreased when used in combination with Bifeprunox. |
| Amitriptyline | The risk or severity of adverse effects can be increased when Amitriptyline is combined with Bifeprunox. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Bifeprunox. |
| Imipramine | The risk or severity of adverse effects can be increased when Imipramine is combined with Bifeprunox. |
| Nortriptyline | The risk or severity of adverse effects can be increased when Nortriptyline is combined with Bifeprunox. |
| Amoxapine | The risk or severity of adverse effects can be increased when Amoxapine is combined with Bifeprunox. |